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Abstract
Background: Data is lacking on comorbid personality disorders (PD) and fibromyalgia syndrome (FMS) in terms of
prevalence, and associated healthcare and societal costs. The main aim of this study was to assess the prevalence of
PD in FMS patients and to analyse whether the presence of comorbid PD is related to worse functional impairment
and greater healthcare (medical visits, drug consumption, and medical tests) and societal costs.
Methods: A cross-sectional study was performed using the baseline data of 216 FMS patients participating in a
randomized, controlled trial carried out in three primary health care centres situated in the region of Barcelona, Spain.
Measurement instruments included the International Personality Disorder Examination - Screening Questionnaire
(IPDE-SQ), the Fibromyalgia Impact Questionnaire (FIQ), the Client Service Receipt Inventory (CSRI), and a
socio-demographic questionnaire.
Results: Most patients (65 %) had a potential PD according to the IPDE-SQ. The most prevalent PD were the avoidant
(41.4 %), obsessive-compulsive (33.1 %), and borderline (27 %). We found statistically significant differences in functional
impairment (FIQ scores) between FMS patients with potential PD vs non-PD (59.2 vs 51.1; p < 0.001). Multivariate
regression analyses revealed that higher FIQ total scores and the presence of potential PD were related to more
healthcare costs (primary and specialised care visits).
Conclusions: As expected, PD are frequent comorbid conditions in patients with FMS. Our results suggest that the
screening of comorbid PD in patients with FMS might be recommendable in order to detect potential frequent
attenders to primary and specialised care.
Keywords: Fibromyalgia syndrome, Personality disorders, Direct costs, Indirect costs
Background
Fibromyalgia syndrome (FMS) is a complex entity recog-
nised as an illness by the World Health Organisation
(WHO) in 1992 and described in the International Classifi-
cation of Diseases (ICD-10) under code number M79 [1].
Aetiology is unknown and the course of the illness is
chronic. FMS diagnosis is clinical and to date there is no
cure, only treatment of symptoms [2]. FMS is characterized
by multifocal pain, fatigue, non-restorative sleep, subjective
cognitive problems, high levels of distress, and is usually
associated with somatic illnesses such as irritable bowel
syndrome, migraine, etc. In 1990, the American College of
Rheumatology (ACR) established two diagnostic criteria
[3]: firstly, the presence of generalised pain for at least three
months and, secondly, detection of hypersensitivity in at
least 11 of the 18 predefined points on digital application
of a force of 4kgs per surface unit. In May 2010, the ACR
published new diagnostic criteria [4] that eliminate the
tender point examination. FMS diagnosis according to
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ACR 2010 criteria is based on three key elements: (a)
Widespread Pain Index and Symptom Severity Scale above
specific cut-off scores, (b) symptoms have been present at
a similar level for at least 3 months, and (c) the patient
does not have another medical condition that would ex-
plain the symptoms.
Prevalence estimates for FMS in the general population
have varied from 2 % to 4 % in most studies [5]. Prevalence
in primary care consultancies have varied between 5 % and
8 % while rheumatology services report prevalences be-
tween 10 % and 20 % [6, 7].
The high prevalence of FMS and its great impact on
functioning can lead to considerable direct (health re-
sources) and indirect (temporary or permanent unemploy-
ment due to incapacity) economic costs. According to a
study by Sicras-Mainar and colleagues [8], the annual cost
per patient in Spain is more than 9,000€, approximately
5,000€ more than the reference population. In the U.S., the
annual cost of a FMS patient is triple that of the reference
population [9].
To be able to offer adequate treatment, it is important
to bear in mind the comorbid conditions that patients
present with as these can predict quality of life, functional
capacity, and the use of health services by these patients
[10–12].
Little-studied comorbid disorders in FMS are personality
disorders (PD). According to some studies [13–15], be-
tween 31 % and 63 % of patients with FMS may have a PD.
These studies differ in type of sample and assessment
instruments but all agree that the proportion of PD de-
tected in patients with FMS is far greater than that found
in the general population; estimated to be between 6 % and
13 % by some studies [16]. Other studies, in contrast, have
found a similar percentage of PD to those found in the
general population [17]. According to these studies, the
most prevalent PD detected in patients with FMS are those
categorised as Cluster C disorders in the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR), e.g.,
avoidant, obsessive-compulsive and, on the other hand,
borderline personality disorder found in Cluster B [18]. In a
study by Blasco Claros et al. [19], it was concluded that
patients with FMS have fewer narcissistic, histrionic, and
antisocial personality traits than in the general population.
The aims of this study are, firstly, to assess the prevalence
of potential PD in a sample of patients with FMS and,
secondly, to determine whether comorbid FMS and PD
result in a greater degree of functional deterioration than in
patients with FMS only. Finally, to evaluate whether health
care costs associated with patients with FMS and PD are
higher than those for patients without PD.
Methods
In the present work, we used the FibroQoL study base-
line dataset [20, 21]. The FibroQoL study was a 12-
month, randomised controlled trial whose main aim was
to assess the effectiveness and cost-utility of a psycho-
educational intervention for FMS patients compared with
usual care (http://clinicaltrials.gov/show/NCT00550966).
A detailed description of the study protocol can be found
elsewhere [22].
Participants
The FibroQoL study had the following inclusion criteria:
Patients aged 18–75 years, contactable by telephone, and
who met the 1990 ACR criteria for FMS were candidates
for inclusion in the study. Patients with cognitive impair-
ment, presence of physical/psychiatric limitations that
impeded participation in the study assessments, or life
expectancy of less than 12 months were excluded. The
sample pool was composed of all patients included in the
FMS database at the Viladecans Hospital (Barcelona,
Spain), from 2005 to 2008, who were referred by general
practitioners from three Primary Health Centres to the
rheumatology service to confirm a diagnosis of FMS.
Procedure
The potential participants were screened through an initial
phone interview and were provided a general overview of
the study. A research assistant then made an appointment
for those patients that agreed to participate in the study.
Finally, the research assistant, who was not involved with
the treatment and was blind to group allocation, performed
all the face-to-face interviews. Data were collected at base-
line, upon completion of the intervention, (2 month) and at
6 and 12-month follow-up. For the present work, only
baseline data were analysed. IPDE-SQ data were collected
upon completion of the intervention. Figure 1 illustrates
the flow of participants through this study.
Instruments
Socio-demographic questionnaire
Collected information on the following variables: gender,
date of birth, marital status, living arrangements, educa-
tional level, and work status.
Fibromyalgia impact questionnaire
(FIQ) [23, 24]. Measure of functional status that includes
10 items. The first item addresses the ability to perform
physical tasks. In the Spanish version, this physical func-
tion item contains 9 sub-items rather than the original
10. Items 2 and 3 ask the patient to mark the number of
days they felt well and the number of days they were
unable to work because of FMS symptoms. Items 4 to
10, inclusive, rate work difficulty, pain, fatigue, morning
tiredness, stiffness, anxiety, and depression. The FIQ has
a maximum total score of 80 (excluding job-related
items), with higher scores indicating greater impact.
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Client service receipt inventory—adapted
(CSRI) [25, 26]. The CSRI variant used in this study was
designed to collect retrospective data on medication and
service receipt: Medication. A profile of the patient’s use of
all prescribed medications was requested. Service receipt.
The main categories were: emergency service (total visits),
general medical inpatient hospital admissions (total days);
outpatient health care services (total visits to general practi-
tioner, nurse, social worker, psychologist, and other com-
munity health care professionals). Patients were also asked
about type and number of medical tests administered. The
CSRI was administered in all assessments with varying time
frames (the previous 3 months at baseline).
Descriptions of costing procedure
Direct health care costs were calculated by adding the costs
derived from medication consumption, medical tests, and
use of health-related services. The cost of medication was
calculated by determining the price per milligram during
the study, according to the Vademecum International (Red
Book; edition 2008), and included value-added tax. Total
costs of medications were calculated by multiplying the
price per milligram by the daily dose in milligrams and the
number of days receiving such treatment. The main source
of unit cost data related to medical tests and use of health
services was provided by the official tariffs published in the
Official Bulletin of the Catalonia Government for 2008.
Indirect costs were calculated by multiplying the number of
days on sick leave by the minimum daily wage in Spain for
2008. Finally, total costs were calculated by adding direct
and indirect costs. The unit costs are expressed in Euros (€)
based on 2008 prices.
International Personality Disorder Examination – Screening
Questionnaire (IPDE-SQ)
PD screening was performed using the DSM-IV version of
the IPDE-SQ [27, 28]. The IPDE-SQ is a brief, efficient
screening questionnaire. It consists of 77 true/false self-
report items intended to assess PD. Its psychometric prop-
erties have not been studied in depth, but there are some
studies with small samples that have found a sensitivity
near 1.00 and a specificity around 0.60 [29, 30]. The IPDE-
SQ manual recommends a change in the cut-off depending
on the population or study aim. To increase specificity, we
used a more conservative cut-off point; increasing the cut-
off by two points (from ≥ 3 to ≥ 5). This procedure has been
used in previous studies [31–35].
Statistical analyses
Characteristics of the sample assessed with the IPDE-SQ
were compared to those of the FibroQoL study sample that
was not assessed with the IPDE-SQ to test the representa-
tiveness of the former. Descriptive statistics were presented
in terms of means and standard deviations for continuous
Fig. 1 Flow diagram of the participants in the FibroQoL study who completed the IPDE-SQ
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variables and absolute and relative frequencies for categor-
ical variables. For each type of PD (according to IPDE-SQ)
the percentage over the total of PD diagnoses was obtained
(in addition to the percentage over the sample). Bivariate
analysis of continuous outcomes was assessed by comput-
ing means and SDs for each response category of the inde-
pendent variables and performing a t-test or ANOVA to
test for possible differences between categories. Finally,
multivariate regression models were constructed for global
direct costs, medications, tests, primary care services and
specialised services, taking as explanatory variables age,
years with diagnosis and FIQ score. Given the positively-
skewed distributions (truncated at 0) of the dependent vari-
ables, Tobit models were adjusted. As our interest lay in
the observed variables rather than the latent variables that
Tobit models regress, Tobit coefficients were transformed
[36] and 95 % CIs bootstrapped.
Results
Presence of potential PD
Of the 216 participants in the FibroQol study, 157
(72.7 %) completed the IPDE-SQ and of these, 102
(65.0 %) had a possible PD. The most prevalent PD in
the studied sample were avoidant personality disorder
(41.4 %), obsessive-compulsive personality disorder
(33.1 %) and borderline personality disorder (27 %).
Table 1 shows the distribution of PD types and the clus-
ters they belong to, according to the IPDE-SQ results.
There was an ample percentage of participants with
more than one possible PD diagnosis. Only 19.7 % of pa-
tients had one potential PD while 20.4 % of the sample
presented three or more (see Table 2). Multiple overlaps
were also observed with only 41 (40.2 %) of the 102
patients having potential PD from the same cluster, 49
(48 %) having possible PD from 2 different clusters and
12 (11.8 %) from three different clusters.
With respect to the interaction between the potential
PD present in a single patient from distinct clusters, only
3 patients of the 35 with a PD diagnosis of Cluster A had
no diagnoses from other clusters. Eight of 51 patients had
a Cluster B diagnosis only, and 30 of the 89 had a Cluster
C diagnosis only. The least frequent interactions were
Cluster A with Cluster B (14 of 102; 13.7 %) and the most
frequent were Cluster B with Cluster C (41 of 102; 40.2 %)
(Online Resource 1).
No statistically significant differences were found in ei-
ther socio-demographic or health cost variables between
those patients who were assessed with the IPDE-SQ and
those who were not. We only found marginally significant
differences in functional status (FIQ total score) between
the patients that were evaluated with the IPDE-SQ and
those that were not evaluated, with the latter being slightly
more deteriorated (Online Resource 2).
Relationship between potential PD and functional status
(FIQ score)
Table 3 shows, from the bivariate analysis, how the func-
tional status of people with FMS, measured using the
FIQ, did not vary with respect to age, gender, years with
FMS diagnosis, work status, marital status or living ar-
rangements. There were differences according to educa-
tional level as those with more than primary education
were slightly less deteriorated than those with primary
education only.
Significant differences were found on the FIQ de-
pending on whether the patient had a potential PD or not
(p < 0.001). The FIQ value went from 51.1 (FMS without
PD) to 59.2 (FMS + PD). The difference between the two
groups on the FIQ was 8.1 points, which is considered a
minimal clinically important difference1 [37]. The results of
the multivariate regression model for the FIQ total score
showed that presence of a possible PD is a variable that
significantly predicts FIQ score (potential PD B = 7.55,
Table 1 Potential personality disorders (PD) derived from the IPDE-
SQ scores




Avoidant C 65 27.3 41.4
Obsessive-compulsive C 52 21.8 33.1
Borderline B 43 18.1 27.4
Schizoid A 24 10.1 15.3
Schizotypal A 14 5.9 8.9
Dependent C 13 5.5 8.3
Histrionic B 13 5.5 8.3
Narcissistic B 8 3.4 5.1
Paranoid A 6 2.5 3.8
Antisocial A 0 0.0 0.0
Table 2 Number of personality disorders (PD) for FMS patients and
for FMS patients with at least 1 potential PD diagnosis, derived from
the IPDE-SQ scores
Patients Diagnosis
Number PD N % N %
0 55 35.0 0 0
1 31 19.7 31 13.0
2 32 20.4 64 26.9
3 23 14.6 69 30
4 9 5.7 36 15.1
5 5 3.2 25 10.5
6 1 0.6 6 2.5
7 1 0.6 7 2.9
Total 157 100.00 238 100.00
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p = 0.003), while variables such as age or years with diag-
nosis were not significant (p > 0.05).
Relationship between potential PD and direct/indirect costs
(CSRI)
According to the bivariate analysis, direct costs varied in
line with the FIQ and depending on whether a potential
PD was present or not. The higher the FIQ score, i.e., the
greater the functional deterioration, the higher the associ-
ated direct costs (p < 0.001). The presence of a possible
PD was also related to higher direct costs (p < 0.008).
However, these variables were not significantly associated
with indirect costs (Online Resource 3).
Table 4 shows a breakdown of direct costs (medical
tests, medication, primary care assistance and specialised
care). It can be seen that the FIQ score does have a sig-
nificant effect on primary health care service and specia-
lised care costs. The relationship between the FIQ score
and costs associated with medical tests is also close to
significance. Having a potential PD also has an effect on
the same factors, increasing primary care and specialised
care costs.
In contrast, the socio-demographic variables do not have
an impact on the distinct direct costs assessed (Online Re-
source 4).
Tables 5 and 6 show the Tobit multivariate regression
models that were performed to determine which factors
were associated with specific direct costs. The FIQ score
has a significant relationship with direct costs in patients
with and without a possible PD. In other words, the
higher the FIQ score, the higher the costs. If we consider
the intercept, which indicates the mean cost of the mean
patient, we observe that costs associated with patients
with potential PD are higher, with a confidence interval
with values far higher than those for patients without
potential PD.
Regarding medical tests, the FIQ score is significant for
patients with and without possible PD. For costs related to
primary care, the FIQ is only significant in the case of
potential PD. If no PD is present, a higher FIQ score is
not associated with higher costs. A great difference can be
observed between the two groups with respect to the
intercept where FMS patients with a potential PD show
more costs related to primary care visits. In specialised
care great differences are again seen between patients with
possible PD and those without. In both cases, the FIQ
score has an impact on costs. Differences were also found
between the two groups with respect to age: in the group
of patients without PD, the older the individual, the higher
the costs, while in the potential PD group, the older the
patient, the lower the costs. With regard to the ‘medical
tests’ variable, no significant association was found.
Discussion
This study focused on the presence of potential PD in
patients with FMS and found that 65 % of patients met
criteria for a potential PD according to the IPDE-SQ. This
prevalence may seem high but does not differ much from
data found in the literature. In a study carried out in Brazil
[13], 47 women with FMS were assessed through a clinical
interview in a hospital setting. Some 63 % were diagnosed
with a PD (vs. 8 % of controls). Another study [14] per-
formed in France evaluated a sample of 30 outpatients
with FMS using the SCID-II instrument. A total of 46.7 %
were diagnosed with at least one PD with the most preva-
lent disorders being obsessive-compulsive (30 %), border-
line (16.7 %), and depressive (16.7 %). More recently, in a
study conducted in Turkey, the SCID-II was administered
to 103 patients with FMS in a hospital rheumatology unit
Table 3 Bivariate analysis of FIQ scores according to socio-
demographic characteristics and potential personality disorders (PD)
N FIQ p
Age 0.75
[33, 45] 24 53.5 (15.6)
(45,50] 18 54.2 (10.5)
(50,55] 34 57.8 (14.0)
(55,60] 35 56.2 (13.9)
(60,65] 31 57.3 (11.0)
(65,75] 15 58.5 (10.5)
Gender 0.55
Woman 154 56.5 (13.0)
Men 3 50.8 (13.6)
Years with diagnosis 0.48
[0,5] 24 52.1 (16.7)
(5,10] 32 56.2 (12.2)
(10,20] 34 56.9 (11.6)
(20,50] 25 57.4 (13.9)
Working status 0.27
Employed 54 55.0 (13.4)
Non employed 91 57.4 (12.5)
Marital status 0.14
With partner 126 55.7 (13.3)
Without partner 31 59.1 (11.1)
Living arrangement 0.57
Live alone 146 56.5 (13.0)
Live with others 11 54.3 (12.1)
Educational level 0.04
> Primary school 46 53.0 (12.5)
≤ Primary school 111 57.7 (12.9)
PD <0.01
No 55 51.1 (13.2)
Yes 102 59.2 (12.0)
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(vs. 83 controls). The percentage of participants with PD
was lower; 31.1 % (vs. 13.3 % in controls). Regarding the
type of PD, 23 % were obsessive-compulsive, 10 % avoi-
dant and 11 % passive-aggressive [15].
Our study used the IPDE-SQ for assessment of PD. The
developers of the instrument describe it as a screening
tool with high sensitivity and low specificity. Various stud-
ies have changed the cut-off point to increase specificity.
For instance, Lewin and colleagues explored whether it
was better to vary the cut-off point according to the num-
ber of diagnostic criteria corresponding to each PD in the
ICD-10, i.e., a cut-off point of 3, 4 or 5 depending on the
type of PD. This formula appears to give good results [32].
Fernández del Río attempted to replicate these results,
comparing the IPDE-SQ with the IPDE using two distinct
statistical methods, but did not find conclusive results as
discrepancies arose depending on the PD and the method
selected. The cut-off points were 4/5, except in the case of
antisocial personality disorder, which only required a cut-
off point of 3 [33].
In our sample, the presence of potential PD taking a
reference cut-off point of 3 was extremely high (97.5 %).
This is consistent with the results of another study carried
out in primary care which also used the IPDE-SQ with the
same cut-off point (96.7 %) [38]. As such, based on previous
studies, the decision to use a cut-off point of 5 in our study
aimed to offer a more conservative perspective. With this
higher cut-off point, our results show that 65 % of patients
with FMS suffer from a possible PD with the most preva-
lent being the avoidant (41.4 %), obsessive-compulsive
(33.1 %) and borderline (27.4 %). Another important aspect
is that only 20 % presented a single possible PD while,
among the other patients, double or triple possible diagno-
ses were made. Multiple diagnoses are, in general, common
in studies of PD [39].
It is important to stress that all PD apart from the anti-
social are represented. The least frequent are the paranoid
and the narcissistic. These three types of PD are charac-
terised by a lack of empathy and an aggressive interpersonal
style. Various studies have attempted to determine whether
FMS sufferers have any distinctive traits with respect to the
general population. In the meta-analysis carried out by
Malin [40], it was shown that there is no clear evidence that
this is the case. It should be borne in mind that the the
assessment of PD through questionnaires is somewhat
controversial due to the limitations involved [41]. Neverthe-
less, in almost all the cited studies, the prevalence of PD is
higher in the population with FMS than in the general
population (an estimated 6–10 % of people in the commu-
nity have a PD) [16].









FIQ p = 0.24 p = 0.06 p = 0.02* p < 0.01*
[15,40] 20 84.5 (113.1) 84.9 (106.1) 81.0 (82.8) 90.4 (83.0)
(40,50] 25 100.1 (133.8) 125.7 (137.3) 123.5 (154.3) 145.2 (196.1)
(50,60] 41 229.9 (544.7) 131.4 (134.8) 103.6 (76.4) 148.5 (109.9)
(60,70] 47 222.3 (284.0) 186.9 (160.6) 183.9 (218.1) 399.6 (532.9)
(70,90] 24 110.4 (208.2) 271.7 (493.5) 240.1 (316.9) 332.5 (358.2)
PDb p = 0.24 p = 0.71 p = 0.03* P < 0.01*
No 55 132.3 (236.1) 154.3 (155.7) 110.6 (114.5) 156.7 (148.0)
Yes 102 190.6 (382.1) 167.1 (270.2) 169.4 (223.6) 290.9 (423.8)
Note: For each cost variable the table presents its mean (M) and standard deviation (SD)
*p-value for the t-test/ANOVA for differences in costs
bComparisons FMS + PD vs. FMS without PD. We computed Cohen’s d (rule of thumb: 0.20 = small; 0.50 =medium; 0.80 = large). The magnitude of the effect size
was small to medium in both primary care services (d = 0.31) and in specialist services (d = 0.38)
Table 5 Multivariate Tobit regression models on Direct Costs (Medication, Tests)
Direct costs Medication Tests
No PD PD No PD PD No PD PD
(Intercept) 583.4 (478.0, 692.9) 785.2 (643.2, 949.8) 98.9 (50.3, 186.1) 155.2 (100.7, 241.7) 125.2 (60.6, 204.1) 136.1 (90.1, 179.5)
Age −3.1 (−14.8, 7.2) −25.2a (−40.9, −12.4) −4.0 (−11.6, 1.5) −5.1 (−12.9, 0.7) 0.6 (−6.2, 6.9) −5.5 (−11.1, −0.8)
Years with diagnosis 2.4 (−6.9, 12.6) 4.1 (−15.5, 21.6) 3.2 (−1.6, 7.6) 4.6 (−3.3, 17.0) −1.3 (−6.9, 4.8) −0.8 (−8.3, 4.2)
FIQ 12.3a (6.3, 20.2) 20.8a (7.1, 39.0) 2.7 (−0.8, 9.0) 1.6 (−3.2, 5.6) 3.3a (0.2, 6.6) 5.2a (0.9, 12.7)
Note: Transformed Tobit coefficients with bootstrapped 95 % CIs (aindicating statistically significant coefficients –alpha = 0.05-). Explanatory variables centred to
the sample mean. Accordingly, Intercept approximates the cost of a “mean individual” (aged 55.22, with 14.2 years with diagnosis, and a FIQ score of 56.36). For
clarity, significant results are in bold
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In the case of patients with a potential PD, the global FIQ
score is significantly higher and, as such, implies greater
functional deterioration. This finding is consistent with
those observed in other studies on the effects of PD on
functional status and quality of life. These studies gather
data on difficulties in maintaining instrumental roles, pro-
ductive roles, or good social functioning [16, 42]. Chen
[43], in a longitudinal study, showed how quality of life is
more deteriorated in adults who have suffered from a PD
from a young age (Axis II of DSM-IV) than in those who
present Axis I mental disorders.
Focusing on direct costs, the analysis indicated that pa-
tients with a potential PD report more costs related to
primary and specialised care visits than FMS patients with-
out a potential PD. No differences were found regarding
costs associated with consumption of medication or com-
plementary tests, nor were differences detected with respect
to indirect costs.
Differences were observed between the group of patients
with and without potential PD with regard to age. In the
group without potential PD, the older the patient, the
higher the costs while, in contrast, in the potential PD
group, the older the patient, the lower the costs. This may
be because patients with potential PD, being more severe,
are referred more promptly to specialised services while
the opposite could be the case for those without PD. These
data are in accord with those found in some studies which
analysed the relationship between the number and type of
medical comorbidities in FMS, and functional disability
and use of medical services. It has been observed that the
number of comorbidities is one of the factors which ex-
plains medical costs on FMS [12, 44]. Psychiatric comor-
bidities determine medical service use to a greater extent
than so-called functional illnesses [10]. In a study of the
factors which have an impact on FMS costs, it was shown
that comorbid illnesses contribute to direct costs in such a
way that an increase of 20 % is seen for each additional
comorbidity [45].
It should be pointed out that people with a PD (without
FMS) tend to use more medical services than those without
a PD [46]. According to Olssøn [47], having a PD is associ-
ated with more frequent occurence of somatic illnesses and
patients report more muscular pain, asthma, FMS, and
alcohol problems than controls. Moreover, they tend to
take non-prescribed analgesic and anti-depressant medica-
tion, consult their GP more, are referred less frequently to
somatic specialists, and are less satisfied with their last visit
to their GP.
As we pointed out in a previous study using FibroQoL
data [48], an important limitation is that the recruited
participants are not representative of all Spanish regions
and probably of the Spanish general population with FMS.
Our patients were voluntarily participating in a RCT, so
they were highly motivated. They were the type of patients
that present to rheumatology services, agree to participate
in research projects, and meet specific inclusion criteria.
In the present work, this limitation is even greater, be-
cause our sample only reflects the results of 157 out of
484 initially screened patients. Therefore, it is likely that
the amount of PD being assessed are much greater than
would be seen in a study of FMS in the general population
(over-estimation and channeling bias). Replicating our
findings in a community primary care setting would be a
good follow-up to this investigation.
Another important limitation of the present work is the
use of a screening instrument (IPDE-SQ) instead of a
structured clinical interview. In other words, there is a risk
of heightened false positives. Due to problems concerning
the validity of the usual cut-off of three for the IPDE-SQ
in some populations (e.g. prisoners, adult individuals seek-
ing speech treatment for stuttering, etc.), a cut-off point of
responding affirmatively to five or more answers was
applied here. We think that this cut-off modification par-
tially resolves the problem of over-diagnosis because some
previous studies have indicated that the presence of Axis
II disorders is largely consistent when comparing adjusted
screen scores with structured clinical interviews [49].
We consider it important to address in future studies
how having a comorbid PD affects the effectiveness of
pharmacological and non-pharmacoloical treatments for
FMS. We have not found any studies that deal with this
aspect although there are studies that have examined how
having a PD affects the severity and treatment of Axis I
mental disorders. In a 2003 review, it was concluded that
PD could cause a poor result in the treatment of an Axis I
disorder [50]. Other studies demonstrate the need to vary
Table 6 Multivariate Tobit regression models on Direct Costs (Primary and Specialist Services)
Primary care services Specialist services
No PD PD No PD PD
(Intercept)– 87.2 (66.5, 113.2) 138.3 (106.5, 186.4) 146.2 (107.5, 184.7) 214.3 (151.5, 298.7)
Age −1.2 (−3.4, 0.9) −3.0 (−8.2, 0.7) 3.9a (0.5, 7.0) −9.3a (−16.6, −2.4)
Years with diagnosis 2.8 (−0.9, 8.0) −1.2 (−6.0, 3.6) −2.6 (−6.2, 0.6) 0.8 (−8.4, 7.9)
FIQ 1.7 (−0.2, 3.0) 4.8a (1.2, 10.0) 3.9a (1.8, 6.2) 9.0 a (3.4, 16.3)
Note: Transformed Tobit coefficients with bootstrapped 95 % CIs (aindicating statistically significant coefficients –alpha = 0.05-). Explanatory variables centred to
the sample mean. Accordingly, Intercept approximates the cost of a “mean individual” (aged 55.22, with 14.2 years with diagnosis, and a FIQ score of 56.36). For
clarity, significant results are in bold
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the type of treatment for major depression according to
whether a PD is present or not [51]. It has also been ob-
served that suffering from a PD increases the possibility of
abandoning treatment for an Axis I disorder if the PD is
not also treated [52].
There is consensus among experts that FMS is far from
being a homogeneous clinical entity and that subgroups of
patients may be identifiable [53]. Data from the present
study suggests that routine screening in primary health
care services of comorbid PD among FMS patients might
be a cost-effective strategy. This subtype of FMS patients
with comorbid PD significantly consumes more healthcare
resources, mainly primary care and specialized services.
The early detection of a potential PD might set in motion
tailored treatments addressed to this subgroup of patients,
which are very likely to be treatment resistant. If “one-size
fits-all” treatment approaches have high probability of
being not effective in the case of FMS due to its hetero-
geneity, managing FMS patients with comorbid PD in the
same way that those without PD is even more likely to be
unsuccessful. It is of paramount importance to provide in-
formation and training to primary care providers in man-
agement strategies for this complex syndrome given that
most FMS patients are attended and monitored in this
level of care. In fact, the management of FMS in primary
health care and the need for training and information for
primary care providers is a current topic of interest among
experts in the field [54, 55].
Conclusion
In conclusion, our study indicates that a high percentage of
patients with FMS present a potential comorbid PD.
Among the most prevalent PD are the avoidant, obsessive-
compulsive and borderline disorders. Patients with FMS
and concomitant possible PD have worse functional status
and higher direct costs, especially in terms of visits to pri-
mary healthcare and specialists.
Data availability
Data available on request.
Endnotes
1In order to test whether the 7 FMS patients with more
than 5 PDs might have biased our results, we also com-
puted the FIQ medians and the interquartile ranges
(IQR). The median is a statistic that is not influenced by
few large values in the data and the IQR is a measure of
dispersion that accompanies the median. It is the distance
between the upper and lower quartiles.FMS + PDs [FIQ
Median = 62.68 (51.94, 67.87)] vs FMS without PDs [FIQ
Median = 51.33 (42.95, 60.59)]; the difference is signifi-
cant at p < 0.001.
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